Adjuvant Sorafenib and Sunitinib and Cardiotoxicity in Renal Cell Carcinoma Patients Without Overt Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients Without Overt Metastases: Results From ASSURE, ECOG2805
Clin. Cancer Res 2015 May 12;[EPub Ahead of Print], N Haas, J Manola, B Ky, KT Flaherty, RG Uzzo, C Kane, MA Jewett, L Wood, CG Wood, MB Atkins, JP Dutcher, G Wilding, R DiPaolaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.